p185和CD44v6在喉鳞状细胞癌中的表达及临床意义

Exprssion and clinical significance of p185 and CD44v6 in laryngeal squamous cell carcinoma

目的:探讨癌基因蛋白p185和细胞黏附因子CD44v6在喉鳞状细胞癌(LSCC)中的表达、临床意义及其相关性。方法:采用免疫组织化学SP法检测63例LSCC及其中20例癌旁安全缘组织(ASM)和18例声带息肉(VCP)中p185与CD44v6的表达。结果:p185在VCP中不表达,在LSCC和ASM中的阳性率分别是74.6%、35.0%,两者之间差异有统计学意义;p185在不同病理分级Ⅰ、Ⅱ、Ⅲ级间存在差异(P<0.05);p185在不同临床分期的表达,差异无统计学意义(P>0.05);CD44v6在LSCC、VCP和ASM中的阳性率分别是96.8%、83.3%、60.0%,3者之间差异有统计学意义(P<0.05);CD44v6在不同病理分级Ⅰ、Ⅱ、Ⅲ级及不同临床分期间的表达差异无统计学意义(P>0.05);LSCC中p185与CD44v6的表达存在正相关(r=0.393,P<0.01)。结论:根据实验结果,p185可能在LSCC发生及发展中起重要作用,CD44v6可能只在LSCC的发生中起作用,在癌旁组织中p185与CD44v6的表达均较良性病变中的表达量增加,反映癌旁移行黏膜中两者可能作为不稳定因素与LSCC复发有关,且两者可能存在协同作用。

Objective： To investigate the expression and the clinical significance of proto-oncogene cerbB-2 proteins p185 and adhesion molecules CD44v6 in laryngeal squamous cell carcinomas （LSCC） and the relationship between them. Method：expression of p185 and CD44v6 was studied by immunohistochemical analysis from 63 cases of LSCC,20 cases of adjacnet safety margin（ASM） and 18 cases of vocal cord polyp（VCP）. Result：There were no expression of p185in VCP, Significant differences（ P〈0.05） were observed between the two group; there was significant differences among the different pathologic degree Ⅰ ,Ⅱ ,Ⅲ ; The expression of p185 was not related to age and clinical stage. Significant differences（ P d0.05） were found among LSCC,VCP and ASM ; there was no differences between the different pathologic degree Ⅰ ,Ⅱ ,Ⅲ. The expression of CD44v6 was not related to age and clinical stage. Significant correlation was observed between the expression of p185 and CD44v6 in LSCC. Conelusion： p185 probably plays an important role during the carcinogenesis and progression process of LSCC. While CD44v6 has the important function only in the carcinogenesis process of LSCC. The expression of p185 and CD44v6 were higher in ASM than in VCP. It indicates that p185 and CD44v6 were probably the unstable factor in ASM which related to the recurrent of laryngeal carcinoma, and they may cooperate with each other.